This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endocyte, Inc's CEO Discusses Second Quarter Results - Earnings Call Transcript

These things often have some tough starts as you go along but they have just been outstanding to work with on all fronts.

Of course, we've also announced that we've named David Meek as our Commercial Head. He's key to the interaction with Merck. We interviewed a number of candidates. We couldn't be happier with landing David. He is kind of the ideal person for this position. He has significant oncology experience.

He's spent the last three or four years in Europe with Novartis and so he'll have great insight into the first launch, which will be in the EU. He's had multiple global marketing and senior leadership sales positions and he was just very – I mean, we're very lucky to get someone of his caliber to come to Endocyte. We look forward to introducing him to – in the future of calls.

The other just update, I guess, is we've already announced, we've added a couple new board members to the board, Pete Meldrum and Marc Kozin. This is consistent with our plan to continue to build the right capabilities on the board as we transition from development into commercial phase of the company and accelerate our pipeline.

So those are the updates and key milestones. I'll let Mike go over the financials and then we'll take questions.

Mike Sherman

Thanks, Ron. This is the first quarter, of course, in which we'll recognize the accounting for the Merck collaboration, so I want to make sure we spend some time covering how that will show up on our financial statement. And more importantly I think you'll see how that collaboration really puts us in a very strong position from a financial standpoint.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.23 0.63%
FB $117.52 -0.89%
GOOG $697.01 -0.17%
TSLA $235.00 -2.80%
YHOO $36.21 -0.88%


Chart of I:DJI
DOW 17,715.05 -176.11 -0.98%
S&P 500 2,059.19 -22.24 -1.07%
NASDAQ 4,760.6130 -56.9810 -1.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs